Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Treatment of multiple sclerosis].

D Fernández Uría1

  • 1Servicio de Neurología, Hospital San Agustín, Avilés, Asturias.

Neurologia (Barcelona, Spain)
|February 5, 2000
PubMed
Summary

Advances in multiple sclerosis (MS) treatments offer hope, but no definitive cure exists. Research focuses on new therapies, combining treatments, and promoting remyelination for improved patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Huntington chorea: clniical and molecular analysis in Asturian patients].

Neurologia (Barcelona, Spain)·1999
Same author

[Locked-in syndrome of mesencephalic origin].

Neurologia (Barcelona, Spain)·1988
See all related articles

Area of Science:

  • Neurology
  • Immunology

Context:

  • Multiple sclerosis (MS) is a chronic neurological disease with ongoing research into effective long-term treatments.
  • Current therapies, including corticoids for acute phases and beta interferon for remittent MS, have limitations and ongoing questions regarding optimal use.

Purpose:

  • To review current and emerging therapeutic strategies for multiple sclerosis (MS).
  • To highlight the limitations of existing treatments and the directions of ongoing research.

Summary:

  • Corticoids are standard for acute MS relapses, with intravenous methylprednisolone being common.
  • Beta interferon is a primary choice for remittent MS, though optimal use and alternatives like copolymer-1 or azathioprine are debated.
  • Interferon beta 1-b shows promise for secondary progressive MS, while primary progressive MS remains challenging.
  • Chemotherapeutic agents like mitoxantrone, methotrexate, and cyclophosphamide may be used for rapidly evolving MS.
  • Current research explores treatment combinations, targeted immunomodulators, and remyelination-promoting therapies.

Impact:

  • Ongoing research aims to develop more specific and effective treatments for MS, potentially modifying disease progression.
  • Symptomatic, pharmacological, and rehabilitation treatments remain crucial for maintaining patient quality of life.

Related Experiment Videos